This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
Guan H, et al. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. Advances in Therapy : 12 Mar 2019. Available from: URL: http://doi.org/10.1007/s12325-019-00908-7
Rights and permissions
About this article
Cite this article
Alectinib not cost effective for NSCLC in China. PharmacoEcon Outcomes News 825, 5 (2019). https://doi.org/10.1007/s40274-019-5771-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5771-3